AUTL compared with PATH: revenue, margins and what each company keeps, and the suppliers and customers both name

AUTLAutolus Therapeutics plc

Mkt capRevenueRevenue

PATHUiPath, Inc.

Mkt capRevenueRevenue

Compare

AUTLAutolus Therapeutics plc

PATHUiPath, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AUTL

No earnings history for AUTL.

PATH1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY27±14.1%▼−16.63%×1.18

= impliedAUTL realized, solidPATH realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

AUTLAutolus Therapeutics plc

1.42· pre 1.42· delayed

Mkt cap$404.6MRevenue$46MQ2 FY26Revenue$75MFY25

PATHUiPath, Inc.

13.31· pre 13.14· delayed

Pre-marketNov 3 '26delayed

Mkt cap$7.0BRevenue$410MQ2 FY27Revenue$1.6BFY26

Compare

Pre-marketNov 3 '26delayed

AUTLAutolus Therapeutics plc

PATHUiPath, Inc.

1.42pre 1.42delayed

Price

13.31pre 13.14delayed

$404.6M

Mkt cap

$7.0B

Q2 FY26$46M

Revenue

$410MQ2 FY27

FY25$75M

Revenue

$1.6BFY26

AUTL1.42vsPATH13.31Pre-marketNov 3 '26delayed